Zacks upgraded San Diego-based Cytori Therapeutics to a "buy" rating from a "hold" rating on Feb. 9, according to InterCooler.
Here are six insights:
1. Zacks has a $0.25 target price on the stock.
2. Zacks' price objective sees an upside of 78.57 percent from the stock's current price.
3. Cytori shares opened at 0.14 on Feb. 9.
4. The market cap is $22.19 million.
5. The company has a 52-week low of $0.14 and a 52-week high of $1.47.
6. The 50-day moving average is $0.18 and the 200-day moving average is $0.32.